Ghent University Academic Bibliography

Advanced

Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment

Wim Ceelen UGent and Marc Bracke UGent (2009) LANCET ONCOLOGY. 10(1). p.72-79
abstract
Roughly one in five patients with colorectal. cancer develops peritoneal minimal residual disease after surgical resection, and about one in seven patients develops peritoneal carcinomatosis. By contrast with the vast body of research addressing haematogenous metastasis, little is known about the biology of peritoneal spread of colorectal cancer. The development of peritoneal carcinomatosis involves well-defined steps including cell shedding and transport, adhesion to the mesothelial layer, invasion of and proliferation into the submesothelial stroma, and potential access to the systemic circulation. In this Review, we summarise the molecular mechanisms and potential preventive measures associated with each step of the peritoneal metastatic cascade.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
INTRAPERITONEAL CHEMOTHERAPY, COLON-CANCER, ALPHA-V-BETA-3 INTEGRINS, SYSTEMIC CHEMOTHERAPY, ADHESION MOLECULES, TUMOR-GROWTH, IN-VITRO, POLYMERASE-CHAIN-REACTION, HUMAN MESOTHELIAL CELLS, OVARIAN-CARCINOMA CELLS
journal title
LANCET ONCOLOGY
Lancet Oncol.
volume
10
issue
1
pages
72 - 79
Web of Science type
Review
Web of Science id
000262216900023
JCR category
ONCOLOGY
JCR impact factor
14.47 (2009)
JCR rank
5/163 (2009)
JCR quartile
1 (2009)
ISSN
1470-2045
DOI
10.1016/S1470-2045(08)70335-8
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
700352
handle
http://hdl.handle.net/1854/LU-700352
date created
2009-06-15 17:02:57
date last changed
2010-05-27 09:24:15
@article{700352,
  abstract     = {Roughly one in five patients with colorectal. cancer develops peritoneal minimal residual disease after surgical resection, and about one in seven patients develops peritoneal carcinomatosis. By contrast with the vast body of research addressing haematogenous metastasis, little is known about the biology of peritoneal spread of colorectal cancer. The development of peritoneal carcinomatosis involves well-defined steps including cell shedding and transport, adhesion to the mesothelial layer, invasion of and proliferation into the submesothelial stroma, and potential access to the systemic circulation. In this Review, we summarise the molecular mechanisms and potential preventive measures associated with each step of the peritoneal metastatic cascade.},
  author       = {Ceelen, Wim and Bracke, Marc},
  issn         = {1470-2045},
  journal      = {LANCET ONCOLOGY},
  keyword      = {INTRAPERITONEAL CHEMOTHERAPY,COLON-CANCER,ALPHA-V-BETA-3 INTEGRINS,SYSTEMIC CHEMOTHERAPY,ADHESION MOLECULES,TUMOR-GROWTH,IN-VITRO,POLYMERASE-CHAIN-REACTION,HUMAN MESOTHELIAL CELLS,OVARIAN-CARCINOMA CELLS},
  language     = {eng},
  number       = {1},
  pages        = {72--79},
  title        = {Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment},
  url          = {http://dx.doi.org/10.1016/S1470-2045(08)70335-8},
  volume       = {10},
  year         = {2009},
}

Chicago
Ceelen, Wim, and Marc Bracke. 2009. “Peritoneal Minimal Residual Disease in Colorectal Cancer: Mechanisms, Prevention, and Treatment.” Lancet Oncology 10 (1): 72–79.
APA
Ceelen, Wim, & Bracke, M. (2009). Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. LANCET ONCOLOGY, 10(1), 72–79.
Vancouver
1.
Ceelen W, Bracke M. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. LANCET ONCOLOGY. 2009;10(1):72–9.
MLA
Ceelen, Wim, and Marc Bracke. “Peritoneal Minimal Residual Disease in Colorectal Cancer: Mechanisms, Prevention, and Treatment.” LANCET ONCOLOGY 10.1 (2009): 72–79. Print.